Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
暂无分享,去创建一个
[1] R. Jain,et al. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. , 1996, British Journal of Cancer.
[2] C. Springer,et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). , 1995, Journal of medicinal chemistry.
[3] I. Niculescu-Duvaz,et al. Antibody-Directed Enzyme Prodrug Therapy (ADEPT): A Targeting Strategy in Cancer Chemotherapy , 1995, Current Medicinal Chemistry.
[4] I. Niculescu-Duvaz,et al. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. , 1994, Journal of medicinal chemistry.
[5] C. Springer,et al. Galactosylated antibodies and antibody‐enzyme conjugates in antibody‐directed enzyme prodrug therapy , 1994, Cancer.
[6] J. Boyle,et al. Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. , 1993, Journal of immunological methods.
[7] K. Bagshawe,et al. ANTIBODY-ENZYME CONJUGATES CAN GENERATE CYTOTOXIC DRUGS FROM INACTIVE PRECURSORS AT TUMOR SITES , 1991 .
[8] C. Springer,et al. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). , 1991, Anti-cancer drug design.
[9] C. Springer,et al. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. , 1991, European journal of cancer.
[10] C. Springer,et al. Antibody directed enzyme prodrug therapy (ADEPT): clinical report. , 1991, Disease markers.
[11] R. Sherwood,et al. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. , 1990, British Journal of Cancer.
[12] S. Sharma,et al. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. , 1990, British Journal of Cancer.
[13] C. Springer,et al. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. , 1990, Journal of medicinal chemistry.
[14] R K Jain,et al. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.
[15] C. Springer,et al. A cytotoxic agent can be generated selectively at cancer sites. , 1988, British Journal of Cancer.
[16] W. Denny,et al. ANTIBODY-DIRECTED ENZYME-PRODRUG THERAPY (ADEPT) , 1996 .
[17] D. Kerr,et al. Generation of cytotoxic agents by targeted enzymes. , 1993, Bioconjugate chemistry.
[18] C. Springer,et al. Synthesis of an N-mustard prodrug , 1990 .